ExelixisEXEL
About: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees: 1,310
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
62% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 50
15% more capital invested
Capital invested by funds: $5.52B [Q2] → $6.33B (+$812M) [Q3]
8% more funds holding
Funds holding: 406 [Q2] → 437 (+31) [Q3]
1.19% more ownership
Funds ownership: 84.41% [Q2] → 85.61% (+1.19%) [Q3]
4% more call options, than puts
Call options by funds: $70.4M | Put options by funds: $67.6M
0% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 7 (+0) [Q3]
14% less repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 159
Research analyst outlook
19 Wall Street Analysts provided 1 year price targets over the past 3 months
19 analyst ratings
Guggenheim Michael Schmidt 54% 1-year accuracy 7 / 13 met price target | 4%downside $33 | Buy Maintained | 30 Oct 2024 |
Stephens & Co. Sudan Loganathan 40% 1-year accuracy 2 / 5 met price target | 16%downside $29 | Equal-Weight Maintained | 30 Oct 2024 |
Piper Sandler Joseph Catanzaro 45% 1-year accuracy 14 / 31 met price target | 5%upside $36 | Overweight Maintained | 30 Oct 2024 |
RBC Capital Gregory Renza 61% 1-year accuracy 45 / 74 met price target | 1%downside $34 | Outperform Reiterated | 30 Oct 2024 |
Truist Securities Asthika Goonewardene 38% 1-year accuracy 10 / 26 met price target | 10%upside $38 | Buy Maintained | 30 Oct 2024 |
Financial journalist opinion
Based on 22 articles about EXEL published over the past 30 days
